Emergent BioSolutions Inc. (EBS)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
Show:
Annual
Cash flow
All numbers in thousandsBreakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-565,300
-760,500
-211,600
219,500
305,800
Depreciation & amortisation
118,400
125,100
143,300
123,800
114,500
Deferred income taxes
-16,400
-8,900
-28,600
46,000
-3,300
Stock-based compensation
22,200
23,100
45,100
42,400
51,800
Change in working capital
-131,700
-70,300
-2,100
-145,000
9,500
Accounts receivable
-74,200
-21,600
118,100
-16,200
27,500
Inventory
26,800
600
-57,100
-66,600
-66,900
Accounts payable
-22,800
10,600
-14,000
-1,600
28,300
Other working capital
-132,200
-257,900
-149,900
96,100
395,000
Other non-cash items
37,200
34,500
13,100
9,000
29,600
Net cash provided by operating activities
-84,900
-206,300
-34,100
320,200
536,900
Cash flows from investing activities
Investments in property, plant and equipment
-47,300
-51,600
-115,800
-224,100
-141,900
Acquisitions, net
-
-
-
-
0
Other investing activities
-
-6,300
-265,500
-
-10,000
Net cash used for investing activities
216,600
212,300
-381,300
-224,100
-151,900
Cash flows from financing activities
Debt repayment
-563,900
-563,400
-33,800
-35,900
-387,100
Common stock issued
-
8,400
0
0
-
Common stock repurchased
-
0
-82,100
-106,000
0
Other financing activities
-800
-2,500
-5,900
-15,000
-25,000
Net cash used provided by (used for) financing activities
-484,500
-535,700
481,200
-141,000
69,700
Net change in cash
-353,800
-530,900
66,300
-45,200
453,500
Cash at beginning of period
430,200
642,600
576,300
621,500
168,000
Cash at end of period
77,400
111,700
642,600
576,300
621,500
Free cash flow
Operating cash flow
-84,900
-206,300
-34,100
320,200
536,900
Capital expenditure
-47,300
-51,600
-115,800
-224,100
-141,900
Free cash flow
-132,200
-257,900
-149,900
96,100
395,000
© 2024 Yahoo. All rights reserved.